Research Article
Clinical Characteristics and Treatment Outcome of 485 Patients with Nonfunctioning Pituitary Macroadenomas
Table 3
Comparison of clinical, endocrine, and tumoral features among patients with null-cell, gonadotrophin-producing, and silent adenomas.
| | | Null-cell () | Gonadotrophinomas () | Silent adenomas () | |
| | Age (years) | 53.2 ± 14.9 | 58.3 ± 12.2 | 41.4 ± 14 | 0.05 | | Females | 24 (50%) | 33% | 62% | 0.11 | | Visual field defects | 85% | 90% | 50% | 0.01 | | Hypothyroidism | 22 | 25 | 3 | 0.9 | | Hypogonadism | 18 | 19 | 1 | 0.38 | | Hypocortisolism | 12 | 20 | 1 | 0.35 | | Panhypopituitarism | 8 | 12 | 0 | 0.36 | | Tumor volume | 13819 mm3 | 11162 mm3 | 4673 mm3 | 0.27 | | Median (IQR) | (8202–20168) | (6900–19476) | (4188–15079) | | Supra- or parasellar extension | 56% | 68% | 50% | 0.8 | | Giant | 27% | 24% | 0% | 0.24 | | Recurrent | 15 | 18 | 1 | 0.56 | | Apoplexy | 3 | 1 | 1 | 0.34 |
|
|
